Retia Medical secures 510(k) green light for its less-invasive cardiac output monitor

operating room
Retia hopes its Argos system will help make cardiac output monitoring the standard for more patients in more settings. (Pixabay)

The FDA granted a 510(k) clearance to Retia Medical’s hemodynamic monitoring device for measuring a patient’s cardiac output in intensive care units or the operating room.

The Valhalla, New York-based company’s Argos monitor uses “multibeat analysis” algorithms and signal processing, which employ a blood pressure waveform derived from up to 20 heartbeats to produce a model of an adult patient’s circulation.

Retia says the monitor will help provide clinicians with accurate data to help track oxygen delivery and maintain the optimal fluid status in high-risk surgical and critically ill patients. In addition, the system integrates with current vital sign monitors and common electronic medical records platforms.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.
The Argos system. (Retia Medical)

“A key challenge in realizing the potential clinical benefits of [cardiac output] monitoring is that many monitors fail to track CO changes accurately when fluid and vasoactive drug therapy are administered,” said Marc Zemel, Retia’s co-founder and CEO. The company says its device and algorithms avoid the confounding effects that can cause inaccuracies in other hemodynamic monitors.

RELATED: Retia Medical pulls in $7M Series A round

Because the Argos device connects directly to a vital sign monitor for information, eliminating the need for disposables with each use, Retia says the device can be much cheaper to own over a longer period of time compared to other hemodynamic monitoring systems. The company also hopes that this will help cardiac output monitoring become the standard of care for more patients in more settings, by reducing the cost and amount of work that has previously limited its use to the most high-risk patients.

Suggested Articles

Genentech committed $200 million in upfront and near-term payments, plus up to $515 million in more distant milestones, for the exclusive rights.

Netherlands-based biotech Vico Therapeutics has signed up biopharma veteran Rupert Sandbrink, M.D., Ph.D., as its new chief medical officer.

French biotech Genfit is cutting its way out of its phase 3 NASH disaster in the summer and cresting two new units.